Compounded Medications Insurance Denial Appeal — Free AI Letter
Insurance denied your compounded medication as 'not FDA approved'? Generate a free appeal letter explaining 503A and 503B compounding rules in minutes.
Why compounded medications denials happen so often
Compounded medications are prepared by a licensed pharmacist for an individual patient when the commercial product is unavailable, when the patient cannot tolerate a commercial formulation, or when the dose, route, or strength is not commercially manufactured. Common categories include hormone preparations (BHRT, testosterone, estradiol), pediatric flavorings and dose adjustments, sterile injectables for clinical trials and rare diseases, specialized topical preparations, sterile ophthalmic preparations, and increasingly the GLP-1 analogues (compounded semaglutide and tirzepatide) made available during commercial shortages. Insurance denials almost universally cite that the compounded product is 'not FDA approved' - which is technically true of every patient-specific compound but legally not the same as 'not coverable.' The Federal Food, Drug, and Cosmetic Act creates two distinct categories of compounding pharmacy (Section 503A patient-specific compounding by state-licensed pharmacies and Section 503B outsourcing facility compounding) that are explicitly authorized by federal law. The appeal often turns on whether the commercial alternative was tried, was unavailable, or caused intolerance.
Why Compounded Rx gets denied
Compounded product 'not FDA approved' - the most common denial language
Commercial alternative available and not tried first
Bulk drug substance not on FDA's 503A or 503B approved bulks list
Compound contains a drug withdrawn from market for safety reasons
Compound considered 'essentially a copy' of a commercially available product
Hormone preparation excluded under plan policy on bioidentical hormone replacement therapy
Compounded GLP-1 (semaglutide, tirzepatide) denied because the commercial product (Ozempic, Wegovy, Mounjaro, Zepbound) is now off the FDA shortage list
Sterile compound from a 503A pharmacy where plan requires 503B for sterile preparations
Federal and state protections for Compounded Rx
Compounded drugs are explicitly authorized by Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act (21 USC sections 353a and 353b). Section 503A covers patient-specific compounding by state-licensed pharmacies. Section 503B covers outsourcing facilities that produce sterile compounded drugs without patient-specific prescriptions and are subject to FDA cGMP inspection. The FDA maintains a Drug Shortage List under section 506C; while a drug is on the shortage list, compounding the active ingredient may be permitted under 503A and 503B. Plan coverage of compounded drugs is governed by the plan contract and pharmacy benefit; ACA-regulated plans must follow 45 CFR section 147.136 for internal appeal and external review. Self-funded ERISA plans must provide full and fair review under 29 CFR section 2560.503-1. State insurance departments enforce coverage standards on fully insured plans and may have specific compound coverage rules.
Evidence checklist for your appeal
- Prescription documenting the patient-specific compounding need (allergy to commercial inactive ingredient, dose not commercially available, alternative route required)
- Documentation that commercial alternatives were tried and failed or are inappropriate
- If shortage-related: FDA Drug Shortage List entry showing the active ingredient was on the shortage list at the time of compounding
- Compounding pharmacy's 503A licensure or 503B outsourcing facility registration
- Letter of medical necessity explaining why the compounded preparation is required
- Manufacturer correspondence documenting unavailability if applicable
- If hormone-related and plan excludes BHRT: identify whether the active ingredients are FDA-approved as monographs and frame the request as customized dose, not investigational therapy
Common products
- Compounded semaglutide (active ingredient in Ozempic, Wegovy)
- Compounded tirzepatide (active ingredient in Mounjaro, Zepbound)
- Compounded estradiol, progesterone, testosterone (BHRT)
- Compounded LDN (low-dose naltrexone)
- Compounded ketamine nasal spray
- Compounded sterile ophthalmic preparations
Insurer-specific patterns and tactics
Most major commercial PBMs (CVS Caremark, Express Scripts, OptumRx) maintain a list of excluded compound ingredients that they will not cover regardless of medical necessity. Some plans now require pre-authorization for any compound exceeding a dollar threshold (often $300). For compounded GLP-1 medications, virtually all commercial plans deny because the commercial products (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved and the compounded versions exist primarily because of cost or shortage workarounds; the appeal angle is unavailability of the commercial product or intolerance to commercial inactive ingredients. Medicare Part D generally does not cover compounded drugs unless every component is otherwise covered.
Generate your Compounded Rx appeal letter
Upload your denial notice or EOB. Our 5-agent AI pipeline drafts a professional appeal that cites the specific statute, clinical policy, and evidence pattern relevant to a compounded rx denial - in about 2 minutes, free.
Upload my denial · Free